These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19016916)

  • 1. Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders.
    Ghaderi M; Strömberg O; Porwit A
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):122-6. PubMed ID: 19016916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
    Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
    Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
    Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
    Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
    Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
    Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
    Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
    Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.
    Er TK; Lin SF; Chang JG; Hsieh LL; Lin SK; Wang LH; Lin CW; Chang CS; Liu TC
    Clin Chim Acta; 2009 Oct; 408(1-2):39-44. PubMed ID: 19595684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].
    Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.
    Chen Q; Lu P; Jones AV; Cross NC; Silver RT; Wang YL
    J Mol Diagn; 2007 Apr; 9(2):272-6. PubMed ID: 17384221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
    Mercier F; Monczak Y; François M; Prchal J; Galipeau J
    Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MPL W515L mutation in Chinese patients with myeloproliferative diseases.
    Xu W; Li JY; Xia J; Zhang SJ; Fan L; Qiao C
    Leuk Lymphoma; 2008 May; 49(5):955-8. PubMed ID: 18464114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes.
    Ruan GR; Jiang B; Li LD; Niu JH; Li JL; Xie M; Qin YZ; Liu YR; Huang XJ; Chen SS
    Hematol Oncol; 2010 Mar; 28(1):33-9. PubMed ID: 19274616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J; Fijnheer R; Walsh IB; Hermans MH
    Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations.
    Vannucchi AM; Guglielmelli P
    Haematologica; 2008 Jul; 93(7):972-6. PubMed ID: 18591622
    [No Abstract]   [Full Text] [Related]  

  • 16. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).
    Koren-Michowitz M; Shimoni A; Vivante A; Trakhtenbrot L; Rechavi G; Amariglio N; Loewenthal R; Nagler A; Cohen Y
    Leuk Res; 2008 Mar; 32(3):421-7. PubMed ID: 17698191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
    Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
    Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
    Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
    Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation.
    Wolstencroft EC; Hanlon K; Harries LW; Standen GR; Sternberg A; Ellard S
    J Mol Diagn; 2007 Feb; 9(1):42-6. PubMed ID: 17251334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms.
    Patnaik MM; Lasho TL; Finke CM; Gangat N; Caramazza D; Siragusa S; Hanson CA; Pardanani A; Tefferi A
    Leukemia; 2010 Apr; 24(4):859-60. PubMed ID: 20111067
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.